Cargando…
Correction: Oral Intake of Royal Jelly Has Protective Effects against Tyrosine Kinase Inhibitor-Induced Toxicity in Patients with Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled Trial. Medicines, 2019, 6, 2
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699318/ https://www.ncbi.nlm.nih.gov/pubmed/33228263 http://dx.doi.org/10.3390/medicines7110071 |
| _version_ | 1783616021325676544 |
|---|---|
| author | Araki, Kyohei Miyata, Yasuyoshi Ohba, Kojiro Nakamura, Yuichiro Matsuo, Tomohiro Mochizuki, Yasushi Sakai, Hideki |
| author_facet | Araki, Kyohei Miyata, Yasuyoshi Ohba, Kojiro Nakamura, Yuichiro Matsuo, Tomohiro Mochizuki, Yasushi Sakai, Hideki |
| author_sort | Araki, Kyohei |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7699318 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | MDPI |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-76993182020-11-29 Correction: Oral Intake of Royal Jelly Has Protective Effects against Tyrosine Kinase Inhibitor-Induced Toxicity in Patients with Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled Trial. Medicines, 2019, 6, 2 Araki, Kyohei Miyata, Yasuyoshi Ohba, Kojiro Nakamura, Yuichiro Matsuo, Tomohiro Mochizuki, Yasushi Sakai, Hideki Medicines (Basel) Correction MDPI 2020-11-19 /pmc/articles/PMC7699318/ /pubmed/33228263 http://dx.doi.org/10.3390/medicines7110071 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
| spellingShingle | Correction Araki, Kyohei Miyata, Yasuyoshi Ohba, Kojiro Nakamura, Yuichiro Matsuo, Tomohiro Mochizuki, Yasushi Sakai, Hideki Correction: Oral Intake of Royal Jelly Has Protective Effects against Tyrosine Kinase Inhibitor-Induced Toxicity in Patients with Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled Trial. Medicines, 2019, 6, 2 |
| title | Correction: Oral Intake of Royal Jelly Has Protective Effects against Tyrosine Kinase Inhibitor-Induced Toxicity in Patients with Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled Trial. Medicines, 2019, 6, 2 |
| title_full | Correction: Oral Intake of Royal Jelly Has Protective Effects against Tyrosine Kinase Inhibitor-Induced Toxicity in Patients with Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled Trial. Medicines, 2019, 6, 2 |
| title_fullStr | Correction: Oral Intake of Royal Jelly Has Protective Effects against Tyrosine Kinase Inhibitor-Induced Toxicity in Patients with Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled Trial. Medicines, 2019, 6, 2 |
| title_full_unstemmed | Correction: Oral Intake of Royal Jelly Has Protective Effects against Tyrosine Kinase Inhibitor-Induced Toxicity in Patients with Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled Trial. Medicines, 2019, 6, 2 |
| title_short | Correction: Oral Intake of Royal Jelly Has Protective Effects against Tyrosine Kinase Inhibitor-Induced Toxicity in Patients with Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled Trial. Medicines, 2019, 6, 2 |
| title_sort | correction: oral intake of royal jelly has protective effects against tyrosine kinase inhibitor-induced toxicity in patients with renal cell carcinoma: a randomized, double-blinded, placebo-controlled trial. medicines, 2019, 6, 2 |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699318/ https://www.ncbi.nlm.nih.gov/pubmed/33228263 http://dx.doi.org/10.3390/medicines7110071 |
| work_keys_str_mv | AT arakikyohei correctionoralintakeofroyaljellyhasprotectiveeffectsagainsttyrosinekinaseinhibitorinducedtoxicityinpatientswithrenalcellcarcinomaarandomizeddoubleblindedplacebocontrolledtrialmedicines201962 AT miyatayasuyoshi correctionoralintakeofroyaljellyhasprotectiveeffectsagainsttyrosinekinaseinhibitorinducedtoxicityinpatientswithrenalcellcarcinomaarandomizeddoubleblindedplacebocontrolledtrialmedicines201962 AT ohbakojiro correctionoralintakeofroyaljellyhasprotectiveeffectsagainsttyrosinekinaseinhibitorinducedtoxicityinpatientswithrenalcellcarcinomaarandomizeddoubleblindedplacebocontrolledtrialmedicines201962 AT nakamurayuichiro correctionoralintakeofroyaljellyhasprotectiveeffectsagainsttyrosinekinaseinhibitorinducedtoxicityinpatientswithrenalcellcarcinomaarandomizeddoubleblindedplacebocontrolledtrialmedicines201962 AT matsuotomohiro correctionoralintakeofroyaljellyhasprotectiveeffectsagainsttyrosinekinaseinhibitorinducedtoxicityinpatientswithrenalcellcarcinomaarandomizeddoubleblindedplacebocontrolledtrialmedicines201962 AT mochizukiyasushi correctionoralintakeofroyaljellyhasprotectiveeffectsagainsttyrosinekinaseinhibitorinducedtoxicityinpatientswithrenalcellcarcinomaarandomizeddoubleblindedplacebocontrolledtrialmedicines201962 AT sakaihideki correctionoralintakeofroyaljellyhasprotectiveeffectsagainsttyrosinekinaseinhibitorinducedtoxicityinpatientswithrenalcellcarcinomaarandomizeddoubleblindedplacebocontrolledtrialmedicines201962 |